139.82
2.45%
+3.34
After Hours:
140.25
0.43
+0.31%
DaVita Inc stock is currently priced at $139.82, with a 24-hour trading volume of 750.33K.
It has seen a +2.45% increased in the last 24 hours and a +9.54% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $137.1 pivot point. If it approaches the $140.1 resistance level, significant changes may occur.
Previous Close:
$136.48
Open:
$137.15
24h Volume:
750.33K
Market Cap:
$12.26B
Revenue:
$12.34B
Net Income/Loss:
$815.64M
P/E Ratio:
27.80
EPS:
5.03
Net Cash Flow:
$920.34M
1W Performance:
+1.67%
1M Performance:
+9.54%
6M Performance:
+45.40%
1Y Performance:
+41.79%
DaVita Inc Stock (DVA) Company Profile
Name
DaVita Inc
Sector
Industry
Phone
303-405-2100
Address
2000 16th Street, Denver, CO
DaVita Inc Stock (DVA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-07-23 | Upgrade | UBS | Neutral → Buy |
Nov-01-22 | Downgrade | Deutsche Bank | Buy → Hold |
Oct-31-22 | Downgrade | UBS | Buy → Neutral |
Aug-19-22 | Resumed | UBS | Buy |
Jun-21-22 | Reiterated | BofA Securities | Underperform |
Sep-10-21 | Initiated | Cowen | Market Perform |
Aug-12-21 | Downgrade | Barclays | Overweight → Equal Weight |
Mar-26-21 | Downgrade | BofA Securities | Neutral → Underperform |
Jan-05-21 | Downgrade | BofA Securities | Buy → Neutral |
Jan-24-20 | Upgrade | Goldman | Neutral → Buy |
Nov-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Oct-25-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Sep-11-19 | Downgrade | William Blair | Outperform → Mkt Perform |
Jul-26-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jan-08-19 | Upgrade | UBS | Sell → Neutral |
Jan-03-19 | Initiated | Deutsche Bank | Buy |
Dec-14-18 | Initiated | Barclays | Overweight |
Nov-28-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
Nov-16-18 | Initiated | UBS | Sell |
Nov-08-18 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
Sep-13-18 | Upgrade | JP Morgan | Underweight → Neutral |
Jan-04-18 | Upgrade | BofA/Merrill | Neutral → Buy |
Dec-12-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
Dec-11-17 | Upgrade | Citigroup | Neutral → Buy |
Dec-07-17 | Upgrade | Raymond James | Outperform → Strong Buy |
Nov-08-17 | Reiterated | RBC Capital Mkts | Sector Perform |
Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
Jun-26-17 | Downgrade | Jefferies | Buy → Hold |
Dec-13-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
DaVita Inc Stock (DVA) Latest News
MSN - MSN
MSN
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
MarketWatch
BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
Zacks Investment Research
Charles Schwab Investment Management Inc. Sells 23,456 Shares of DaVita Inc. (NYSE:DVA) - MarketBeat
MarketBeat
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio Now
Zacks Investment Research
DaVita Inc. stock underperforms Thursday when compared to competitors - MarketWatch
MarketWatch
DaVita Inc Stock (DVA) Financials Data
DaVita Inc (DVA) Revenue 2024
DVA reported a revenue (TTM) of $12.34 billion for the quarter ending March 31, 2024, a +5.77% rise year-over-year.
DaVita Inc (DVA) Net Income 2024
DVA net income (TTM) was $815.64 million for the quarter ending March 31, 2024, a +58.74% increase year-over-year.
DaVita Inc (DVA) Cash Flow 2024
DVA recorded a free cash flow (TTM) of $920.34 million for the quarter ending March 31, 2024, a -14.54% decrease year-over-year.
DaVita Inc (DVA) Earnings per Share 2024
DVA earnings per share (TTM) was $8.80 for the quarter ending March 31, 2024, a +62.36% growth year-over-year.
DaVita Inc Stock (DVA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
DESOER BARBARA J | Director |
May 10 '24 |
Sale |
138.81 |
5,030 |
698,214 |
10,954 |
STAFFIERI MICHAEL DAVID | Chief Operating Officer, DKC |
Mar 13 '24 |
Option Exercise |
52.41 |
50,000 |
2,620,500 |
102,748 |
Rodriguez Javier | Chief Executive Officer |
Mar 06 '24 |
Option Exercise |
67.80 |
750,000 |
50,850,000 |
1,244,480 |
ACKERMAN JOEL | CFO and Treasuer |
Mar 06 '24 |
Option Exercise |
52.41 |
55,000 |
2,882,550 |
195,360 |
STAFFIERI MICHAEL DAVID | Chief Operating Officer, DKC |
Mar 06 '24 |
Option Exercise |
52.41 |
50,000 |
2,620,500 |
87,687 |
Rodriguez Javier | Chief Executive Officer |
Feb 28 '24 |
Option Exercise |
67.80 |
50,000 |
3,390,000 |
531,300 |
Rodriguez Javier | Chief Executive Officer |
Feb 27 '24 |
Sale |
126.87 |
7,397 |
938,467 |
481,300 |
Rodriguez Javier | Chief Executive Officer |
Feb 26 '24 |
Option Exercise |
67.80 |
450,000 |
30,510,000 |
889,002 |
Rodriguez Javier | Chief Executive Officer |
Feb 26 '24 |
Sale |
126.11 |
67,603 |
8,525,130 |
488,697 |
STAFFIERI MICHAEL DAVID | Chief Operating Officer, DKC |
Feb 21 '24 |
Option Exercise |
52.41 |
100,000 |
5,241,000 |
137,687 |
About DaVita Inc
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Cap:
|
Volume (24h):